Related references
Note: Only part of the references are listed.
Article
Critical Care Medicine
Fernando G. Zampieri et al.
Summary: Most randomized trials are traditionally analyzed using frequentist statistical approaches like null hypothesis testing and P values. However, the concept of P values can be difficult to understand and may lead to misinterpretation. Bayesian methods offer an alternative probabilistic interpretation of data, providing a distribution of effect sizes compatible with observed trial data based on prior assumptions. Bayesian reanalysis, although increasingly common, raises concerns about potential bias if priors are not predefined. Standardization of priors in Bayesian reanalysis of clinical trials may be beneficial for the critical care community.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
(2021)
Review
Biochemistry & Molecular Biology
Alessandro Sette et al.
Summary: The adaptive immune system, consisting of B cells, CD4(+) T cells, and CD8(+) T cells, plays varying roles in different viral infections and vaccines. Studies are showing that CD4(+) T cells, CD8(+) T cells, and neutralizing antibodies all play a part in controlling SARS-CoV-2 in COVID-19 cases, emphasizing the importance of understanding adaptive immunity in combating the disease.
Article
Medicine, General & Internal
D. M. Weinreich et al.
Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
R. Libster et al.
Summary: A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV-2 in older adult patients within 72 hours after the onset of mild Covid-19 symptoms found that early administration of high-titer convalescent plasma reduced the progression of Covid-19 in mildly ill infected older adults.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Summary: In a platform trial involving patients hospitalized with Covid-19, among 314 patients who were also being treated with remdesivir, those who received the monoclonal antibody LY-CoV555 did not have better pulmonary function at day 5 than those who received placebo. The trial was stopped for futility.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
M. J. Joyner et al.
Summary: This study found that higher anti-SARS-CoV-2 IgG antibody levels in convalescent plasma were associated with a lower risk of death among patients hospitalized with Covid-19 who were not receiving mechanical ventilation. The association between antibody levels and mortality risk was moderated by mechanical ventilation status, with no significant effect seen in patients who had already received ventilation.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
V. A. Simonovich et al.
Summary: There were no significant differences observed in clinical status or overall mortality between patients treated with convalescent plasma and those who received placebo in the treatment of severe Covid-19 pneumonia. The study results indicate that both groups had similar clinical outcomes and mortality rates after 30 days.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Peter Chen et al.
Summary: LY-CoV555, a neutralizing antibody, showed promising results in reducing viral load, improving symptoms, and lowering the risk of hospitalization among patients with mild or moderate Covid-19. While one of the doses appeared to accelerate the decline in viral load, others did not show significant effects by day 11.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Infectious Diseases
Todd C. Lee et al.
Summary: A Bayesian analysis was conducted to examine the probabilities of remdesivir and systemic corticosteroids in reducing mortality among COVID-19 patients, with corticosteroids showing more potential in reducing mortality in patients with varying oxygen requirements.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Review
Medicine, General & Internal
Perrine Janiaud et al.
Summary: Convalescent plasma treatment showed no significant decrease in all-cause mortality or benefit for other clinical outcomes compared to placebo or standard of care. The certainty of the evidence ranged from low to moderate for all-cause mortality and remained low for other outcomes.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Multidisciplinary Sciences
Steven A. Kemp et al.
Summary: Chronic infection with SARS-CoV-2 can lead to viral evolution and increased resistance to neutralizing antibodies in immunosuppressed individuals treated with convalescent plasma. During convalescent plasma therapy, there were significant shifts in the viral population structure and sensitivity, suggesting strong selection pressure on the virus during treatment.
Editorial Material
Medicine, General & Internal
Sean T. H. Liu et al.
Editorial Material
Hematology
[Anonymous]
LANCET HAEMATOLOGY
(2020)
Article
Medicine, Research & Experimental
Hayley E. Jones et al.
Article
Medicine, General & Internal
Kenneth F. Schulz et al.
BMJ-BRITISH MEDICAL JOURNAL
(2010)
Article
Infectious Diseases
KM Yeh et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2005)
Article
Infectious Diseases
Y Cheng et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2005)
